Bob Clay – TOPRA President, UK; Dr Ian Hudson – CEO, MHRA, UK.
Dr Murray M. Lumpkin – Integrated Development (Regulatory Affairs), Lead for Global Regulatory Systems Initiatives, Global Health | Integrated Development, US.
Sharon Gorman – Pfizer, Chair of symposium working party.
Two years ago, the Heads of Medicines Agencies and European Medicines Agency adopted their high-level strategy to 2020. This ambitious strategy set out plans and priorities for the years ahead. What progress has been made so far? What are the network’s priorities as we move into 2018 and beyond?
Introduction: Part-way through the ambitious Multi Annual Work Plan (MAWP) the landscape has changed, resulting in a refocus on our priorities for the next year.
Ian Hudson – CEO, MHRA, UK
HMA MAWP: Achievements and priorities for 2018
Kristin Raudsepp – Director General State Agency of Medicines, Estonia
EMA MAWP: Achievements and priorities for 2018
Agnès Saint-Raymond – Head of International Affairs, EMA, UK
Panel discussion moderated by chair with today’s speakers plus invited guest Christer Backman – Senior expert International Relations, Office of the Director General, MPA, Sweden and Shaun Stapleton, Reneuron – this is your opportunity to explore the topic more fully.
Ensuring timely decision making and access for patients is a global priority, especially in diseases of high unmet medical need. A push to optimise high-quality evidence generation and increase stakeholder dialogue has been put forward by regulators, health technology assessment bodies and other decision makers, in an effort to facilitate that patient needs are addressed through optimal outcomes and that predictability is optimised during an increasingly evidence-based drug development. The aim of this session is to present stakeholders’ views on current and future initiatives to ensure access for patients through collaboration and tools, as well as to reflect on challenges for R&D activities.
Chair: João Duarte – Associate Director, Europe Regulatory Policy & Intelligence, Takeda
How is the EMA supporting drug development to ensure it is geared towards addressing unmet medical needs?
Michael Berntgen – Head of Product Development Scientific Support Department, EMA
HTA bodies as partners in patient access: how to ensure alignment in evidence expectations
Emily Crowe – Technical Adviser, NICE Scientific Advice Program, National Institute for Health and Care Excellence (NICE), UK
Industry views on current challenges and opportunities on timely approval and access to patients
Simon Bennett – Director, Global Regulatory Policy EU Lead and GEMS Interim Lead, Biogen, UK
Panel discussion with this session’s speakers moderated by chair with above speakers and invited panellist Jordi Llinares, Head of Scientific and Regulatory Management, EMA
Insights on how the EMA, US FDA and Japanese PMDA are working together to deliver better regulatory processes and healthcare, and the impact of initiatives supported by the Bill & Melinda Gates Foundation.
Chair: Carlos Langezaal – Director, Global Regulatory Affairs, Eisai Inc, US
The Office of International Programs within the Japanese PMDA and the collaborations between the PMDA and EMA and other Asian health authorities
Kondo Hideyuki – MHLW/PMDA Liaison Official, International Affairs at the EMA, Japan
Five years experience as EMA liaison official to the US FDA
Sabine Haubenreisser – Principal Scientific Administrator International Affairs, EMA
Introducing the ICMRA (International Coalition of Medicines Regulatory Authorities)
Christer Backman - senior expert, International Relations, Office of the Director General, MPA, Sweden
Panel discussion with this session’s speakers and invited guests Agnès Saint-Raymond – Head of International Affairs, EMA and Dr Murray M. Lumpkin, Deputy Director – Integrated Development, (Lead for Global Regulatory Systems Initiatives), Bill & Melinda Gates Foundation, US
Supported by Pharmalex
Meet your colleagues for drinks and dinner with a UK theme in the Exhibition Hall
No content found
Programme subject to change.